On ECHEMI
Home > Drugs > Epididymitis
Epididymitis
Epididymitis is more common in young and middle-aged people, and can be divided into acute epididymitis and chronic epididymitis according to the course of the disease.
  • Site of disease:

    testis
  • Infectious :

    Not contagious
  • Frequent population:

    Young and middle-aged men
  • Related symptoms:

    Testicular pain swelling and hardening of the epididymis fever thickening of the vas deferens male lower abdominal pain
Related Drugs
Fleroxacin Tablets
Indication: It can be used for respiratory system infections such as acute bronchitis, acute exacerbation of chronic bronchitis and pneumonia caused by bacteria sensitive to this product; urogenital system infections such as cystitis, pyelonephritis, prostatitis, epididymitis, gonorrhea Neisseria urethritis; digestive system infections such as typhoid Salmonella infection and bacterial dysentery; skin and soft tissue infections, bone infections, abdominal infections and pelvic infections, etc.
Manufacturer:

Topfond Pharmaceutical Co., Ltd.

Fleroxacin
Indication: It is used for respiratory system infections such as acute bronchitis, acute exacerbation of chronic bronchitis and pneumonia caused by bacteria sensitive to this product; urogenital system infections such as cystitis, pyelonephritis, prostatitis, epididymitis, gonorrhea Neisseria urethritis; digestive system infections such as typhoid Salmonella infection and bacterial dysentery; skin and soft tissue infections, bone infections, abdominal infections and pelvic infections, etc.
Rufloxacin Hydrochloride Tablets
Indication: Used for lower respiratory tract and urogenital system infections caused by sensitive bacteria.
Manufacturer:

Hubei Sihuan Pharmaceutical Co., Ltd.

AMPICILLIN- ampicillin_injection, powder, for solution
Indication: INDICATIONS AND USAGE
Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections S. pneumoniae, Staphylococcus aureus H. influenzae Bacterial Meningitis E. coli, Listeria monocytogenes, N. meningitidis Septicemia and Endocarditis Streptococcus E. coli, Proteus mirabilis Salmonella Urinary Tract Infections E. coli Proteus mirabilis Gastrointestinal Infections Salmonella typhi Salmonella Shigella Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. Indicated surgical procedures should be performed. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Urethritis in males due to
Adults: Treatment may be repeated if necessary or extended if required. In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months. The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral ampicillin may be made when appropriate.
Bacterial Meningitis.
Adults and children: Neonates (less than or equal to 28 days of postnatal age): Table 1: Dosage in Neonates (less than or equal to 28 days of postnatal age) for Bacterial Meningitis and Septicemia Gestational age (weeks) Postnatal age (days) Dosage less than or equal to 34 less than or equal to 7 100 mg/kg/day in equally divided doses every 12 hours less than or equal to 34 greater than or equal to 8 and less than 28 150 mg/kg/day in equally divided doses every 12 hours greater than 34 less than or equal to 28 150 mg/kg/day in equally divided doses every 8 hours
Septicemia.
Adults and children: Neonates (less than or equal to 28 days of postnatal age): Treatment of all infections should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained. A minimum of 10 days treatment is recommended for any infection caused by Group A beta-hemolytic streptococci to help prevent the occurrence of acute rheumatic fever or acute glomerulonephritis. DIRECTIONS FOR USE Use only freshly prepared solutions. Intramuscular and intravenous injections should be administered within one hour after preparation, since the potency may decrease significantly after this period. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Intramuscular Use: NDC Label Claim Recommended Amount of Diluent Withdrawable Volume Concentration (in mg/mL) 44567-105-10 125 mg 1.2 mL 1 mL 125 mg 44567-100-10 250 mg 1 mL 1 mL 250 mg 44567-101-10 500 mg 1.8 mL 2 mL 250 mg 44567-102-10 1 gram 3.5 mL 4 mL 250 mg 44567-103-10 2 grams 6.8 mL 8 mL 250 mg While Ampicillin for Injection, USP 1 g and 2 g, are primarily for intravenous use, they may be administered intramuscularly when the 250 mg or 500 mg vials are unavailable. In such instances, dissolve in 3.5 or 6.8 mL Sterile Water for Injection, USP or Bacteriostatic Water for Injection, USP, respectively. The resulting solution will provide a concentration of 250 mg per mL. Ampicillin for Injection, USP 125 mg, is intended primarily for pediatric use. It also serves as a convenient dosage form when small parenteral doses of the antibiotic are required. Note: Bacteriostatic Water for Injection, USP is not to be used as a diluent when the product will be used in newborns. For Direct Intravenous Use Add 5 mL Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP to the 125 mg, 250 mg, and 500 mg vials and administer slowly over a 3 to 5 minute period. Ampicillin for Injection, USP 1 g or 2 g, may also be given by direct intravenous administration. Dissolve in 7.4 or 14.8 mL Sterile Water for Injection, USP, or Bacteriostatic Water for Injection, USP, respectively, and administer slowly over at least 10 to 15 minutes. CAUTION: More rapid administration may result in convulsive seizures. For Administration by Intravenous Drip: Reconstitute as directed above ( For Direct Intravenous Use) Room Temperature (25°C) Diluent Concentrations Stability Periods Sterile Water for Injection up to 30 mg/mL 8 hours 0.9% Sodium Chloride Injection, USP up to 30 mg/mL 8 hours 5% Dextrose Injection, USP 10 to 20 mg/mL 1 hour 5% Dextrose Injection, USP up to 2 mg/mL 2 hours 5% Dextrose and 0.45% Sodium Chloride Injection, USP up to 2 mg/mL 2 hours Lactated Ringer’s Injection, USP up to 30 mg/mL 8 hours Refrigerated (4°C) Sterile Water for Injection 30 mg/mL 48 hours Sterile Water for Injection up to 20 mg/mL 72 hours 0.9% Sodium Chloride Injection, USP 30 mg/mL 24 hours 0.9% Sodium Chloride Injection, USP up to 20 mg/mL 48 hours Lactated Ringer’s Injection, USP up to 30 mg/mL 24 hours 5% Dextrose Injection, USP up to 20 mg/mL 1 hour 5% Dextrose and 0.45% Sodium Chloride Injection, USP up to 10 mg/mL 1 hour Only those solutions listed above should be used for the intravenous infusion of Ampicillin for Injection, USP. The concentrations should fall within the range specified. The drug concentration and the rate and volume of the infusion should be adjusted so that the total dose of ampicillin is administered before the drug loses its stability in the solution in use. Piggyback IV Package:
Manufacturer:

WG Critical Care, LLC

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.